The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
By C. Roehrborn, P. Siami, J. Barkin, R. Damião, Kim Major-Walker, I. Nandy, B. Morrill, R. Gagnier, F. Montorsi. European Urology, 2010
754 citations recorded by the source corpus.
Subfields: Psychiatry and Mental health, Pulmonary and Respiratory Medicine, Urology
View Paper: https://www.semanticscholar.org/paper/051f0734f7a1b9baaf245442f0ff9e071344c869
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- A. Bachmann
- J. de la Rosette
- M. Oelke
- A. Descazeaud
- J. N'Dow
- M. Michel
- Mark Emberton
- S. Gravas
Citations in the corpus
- EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. (2013, methodology): “In contrast to earlier studies with only 6–12 mo of follow-up, long-term data have demonstrated that combination treatment is superior to monotherapy with regard to symptom reduction and improvement in Qmax [17,18,20].”